Company: IPHYF
Filing Date: 2025-04-30
Form Type: 20-F
Source: 0001598599-25-000042
Chunk: 179

Company: Innate Pharma SA
Filing Date: 2025-04-30
Form: 20-F
Item: Item 5
Chunk 179
---
 depreciation and amortization, mainly composed of the amortization of the monalizumab and IPH5201 intangible assets. (ii) €0.4 million increase in staff costs allocated to research and development, of which €0.2 million in personnel expenses and €0.2 million in share-based payment expenses,.

As of December 31, 2024, the Company had 139 employees, including Leadership Team members, in research and development functions, compared to 140 as of December 31, 2023.

General and administrative expenses

General and administrative expenses from continuing operations increased by €1.4 million, or 7.8%, to €19.7 million for the year ended December 31, 2024, as compared to €18.3 million for the year ended December 31, 2023. General and administrative expenses represented a total of 27.5% and 24.6% of our total operating expenses before impairment for the years ended December 31, 2024 and 2023, respectively.

The table below presents our general and administrative expenses by nature for the years ended December 31, 2023 and 2024:

                                                           Year ended December 31,                  
                                                           2023                         2024        
                                                           (in thousands)                           
 ────────────────────────────────────────────────────────────────────────────────────────────────────
  Personnel expenses (including share based payments)      € (8,842)                    € (8,556)   
  Non scientific advisory and consulting                   (2,906)                      (3,377)     
  Other expenses (1)                                       (6,540)                      (7,783)     
  Total general and administrative                         € (18,288)                   € (19,716)  

.

(1) Other expenses are related to intellectual property, maintenance costs for laboratory equipment and our headquarters, depreciation and amortization and other general and administrative expenses.

Personnel expenses, which includes the compensation paid to our employees and consultants, decreased by €0.3 million, or 3.2%, to €8.6 million for the year ended December 31, 2024, as compared to personnel expenses of €8.8 million for the year ended December 31, 2023. This decrease mainly results from €0.5 million decrease in share-based payment expenses compensated by an increase in wages of €(0.2) million. As of December 31, 2024, we had